Transdural Revascularization by Multiple Burrhole After Erythropoietin in Stroke Patients With Cerebral Hypoperfusion: A Randomized Controlled Trial
Open Access
- 17 May 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 53 (9) , 2739-2748
Abstract
Background: In patients with acute symptomatic stroke, reinforcement of transdural angiogenesis using multiple burr hole (MBH) procedures after EPO (erythropoietin) treatment has rarely been addressed. We aimed to investigate the efficacy and safety of cranial MBH procedures under local anesthesia for augmenting transdural revascularization after EPO treatment in patients with stroke with perfusion impairments. Methods: This prospective, randomized, blinded-end point trial recruited patients with acute ischemic stroke with a perfusion impairment of grade ≥2 within 14 days of symptom onset, steno-occlusive mechanisms on imaging examinations, and absence of transdural collaterals on transfemoral cerebral angiography. Patients were randomly assigned to receive MBH + EPO or MBH alone. The primary and secondary outcomes were revascularization success (trans-hemispheric and trans-burr hole) at 6 months and adverse events, respectively. Results: We evaluated 42 of the 44 targeted patients, with 2 patients lost to follow-up. The combined and MBH-only (n=21 each) groups showed no differences in demographic characteristics and baseline perfusion parameters. Significantly, more cases of trans-hemispheric (19/21 [90.5%] versus 12/21 [57.1%]) and trans-burr hole (42/58 [72.4%] versus 30/58 [51.7%]) revascularization and significant improvements in perfusion parameters were observed in the combined group relative to the MBH-only group. No differences in treatment-related complications were observed between groups. Even after adjustment for potential covariates, EPO usage was an independent factor of successful hemispheric revascularization in this study (odds ratio, 6.41 [95% CI, 1.08–38.02]). Conclusions: The combination of MBH and EPO is safe and feasible for reinforcing transdural revascularization in acute steno-occlusive patients with perfusion impairments. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02603406.Keywords
This publication has 32 references indexed in Scilit:
- Effectiveness of Burr Holes for Indirect Revascularization in Patients with Moyamoya Disease—A Review of the LiteratureWorld Neurosurgery, 2014
- Erythropoietin: still on the neuroprotection roadTherapeutic Advances in Neurological Disorders, 2012
- Neurosurgical Advances in the Treatment of Moyamoya DiseaseStroke, 2011
- A genome-wide association study identifies RNF213 as the first Moyamoya disease geneJournal of Human Genetics, 2010
- Plasma matrix metalloproteinases, cytokines and angiogenic factors in moyamoya diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Recombinant Human Erythropoietin in the Treatment of Acute Ischemic StrokeStroke, 2009
- Risk factors for postoperative ischemic complications in patients with moyamoya diseaseJournal of neurosurgery. Pediatrics, 2005
- Emerging biological roles for erythropoietin in the nervous systemNature Reviews Neuroscience, 2005
- Multiple burr-hole operation for adult moyamoya diseaseJournal of Neurosurgery, 1996
- Cerebral hemodynamics in ischemic cerebrovascular diseaseAnnals of Neurology, 1991